Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gel Encapsulation Transport System Targets Disease-Related Cells

By LabMedica International staff writers
Posted on 10 Aug 2018
A novel therapeutic approach uses drugs encapsulated within galacto‐oligosaccharide gel capsules to target diseases that have accumulated a high percentage of senescent cells.

Senescent cells are aged or damaged cells that no longer are able to perform their normal roles. More...
These cells interfere with the functioning of the tissue in which they accumulate, and eliminating them is considered to be a promising therapeutic approach.

Investigators at the Institute for Research in Biomedicine (Barcelona, Spain) took advantage of the high lysosomal beta‐galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto‐oligosaccharides and their delivery to lysosomes via endocytosis.

The investigators reported in the July 16, 2018, online edition of the journal EMBO Molecular Medicine that gal‐encapsulated fluorophores were preferentially released within senescent cells in mice. In a model of chemotherapy‐induced senescence, gal‐encapsulated cytotoxic drugs targeted senescent tumor cells and improved tumor xenograft regression in combination with the drug palbociclib.

In a model of pulmonary fibrosis in mice, gal‐encapsulated cytotoxic agents targeted senescent cells, reducing collagen deposition and restoring pulmonary function. In addition, gal‐encapsulation reduced the toxic side effects of the cytotoxic drugs. Thus, drug delivery into senescent cells opened new diagnostic and therapeutic applications for senescence‐associated disorders.

Senior author Dr. Manuel Serrano, head of the cellular plasticity and disease laboratory at the Institute for Research in Biomedicine, said, "This nanocarrier may pave the way for new therapeutic approaches for serious conditions, such as pulmonary fibrosis or to eliminate chemotherapy-induced senescent cells."

Related Links:
Institute for Research in Biomedicine


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.